Literature DB >> 6093549

Nerve Na+-K+-ATPase, conduction, and myo-inositol in the insulin-deficient BB rat.

D A Greene, S Yagihashi, S A Lattimer, A A Sima.   

Abstract

Nerve conduction slowing in acute diabetes in animals has been associated with both a diminished axolemmal transmembrane Na+ potential and a myo-inositol-related defect in nerve Na+-K+-ATPase activity. The interaction between these two potentially related defects, their reversibility, and their possible role in the nerve conduction slowing and axonopathy of diabetes are not well defined. Therefore, the effects of rigorous insulin replacement on peripheral nerve conduction velocity, myoinositol content, and Na+-K+-ATPase activity were studied in the spontaneously diabetic BB-Wistar rat, an animal model that manifests both conduction slowing and a characteristic progressive axonopathy. Twelve weeks of sustained hyperglycemia reduced both motor conduction velocity and Na+-K+-ATPase activity in sciatic nerve. Six weeks of subsequent vigorous insulin replacement normalized the enzymatic defect but only partially corrected diminished nerve conduction velocity. Hence, nerve conduction slowing in diabetic animals may be partly attributable to reduced nerve Na+-K+-ATPase activity, but a less readily reversible component of conduction slowing probably reflects structural alterations that occur in nerve within the first 3 mo of diabetes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093549     DOI: 10.1152/ajpendo.1984.247.4.E534

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  25 in total

1.  The neuropathy of elderly mice.

Authors:  A Robertson; B Day; M Pollock; P Collier
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

2.  Diabetes induced by streptozotocin causes reduced Na-K ATPase in the brain.

Authors:  S F Leong; T K Leung
Journal:  Neurochem Res       Date:  1991-10       Impact factor: 3.996

3.  Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy.

Authors:  A A Sima; V Nathaniel; V Bril; T A McEwen; D A Greene
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

4.  Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat.

Authors:  Y Kuzumoto; S Kusunoki; N Kato; M Kihara; P A Low
Journal:  Diabetologia       Date:  2006-10-25       Impact factor: 10.122

5.  Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.

Authors:  A A Sima; A Prashar; W X Zhang; S Chakrabarti; D A Greene
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat.

Authors:  N E Cameron; M B Leonard; I S Ross; P H Whiting
Journal:  Diabetologia       Date:  1986-03       Impact factor: 10.122

7.  The correlation between sensory nerve conduction velocities and three metabolic indices in rats treated with streptozotocin.

Authors:  P O Julu
Journal:  Diabetologia       Date:  1988-04       Impact factor: 10.122

8.  C-peptide improves autonomic nerve function in IDDM patients.

Authors:  B L Johansson; K Borg; E Fernqvist-Forbes; T Odergren; S Remahl; J Wahren
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

9.  Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol.

Authors:  D A Greene; S Chakrabarti; S A Lattimer; A A Sima
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

10.  Cation permeability of the blood-brain barrier in streptozotocin-diabetic rats.

Authors:  J Jakobsen; G M Knudsen; M Juhler
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.